benign%20prostatic%20hyperplasia
BENIGN PROSTATIC HYPERPLASIA
Benign prostatic hyperplasia (BPH) is a histopathological diagnosis characterized by epithelial cell & smooth muscle cell proliferation in the transition zone of the prostate leading to a non-malignant enlargement of the gland, which may result in lower urinary tract symptoms, including voiding and storage symptoms.
It is commonly called enlarged prostate.
Etiology is unknown but due to its similarity to the embryonic morphogenesis of the prostate has led to the hypothesis that BPH may be the result of "reawakening" in adulthood of embryonic induction processes.

Benign%20prostatic%20hyperplasia Management

Follow Up

  • Patients on watchful waiting should be assessed at 6 months and then annually, provided that there are no absolute indications for surgery and symptoms do not deteriorate
  • Patients on pharmacological therapy should be assessed to determine response to treatment and safety
    • Patients taking alpha blockers, anticholinergics, beta-3 adrenergic agonist, PDE5 inhibitors or combination therapy should be assessed at 4-6 weeks after drug initiation and then every 6-12 months thereafter
    • Patients taking 5-alpha reductase inhibitors should be assessed at 3-6 months after drug initiation and then every 6-12 months thereafter
      • Patients on 5-alpha reductase inhibitors should be monitored with annual DRE and PSA
  • Patients who underwent surgical therapy should be assessed 4-6 weeks after catheter removal to evaluate for treatment response and adverse events
    • No further reassessment is necessary in patients without adverse events and with symptomatic relief
Editor's Recommendations
Most Read Articles
22 Nov 2020
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

4 days ago
Vitamin D deficiency may be a contributing factor to the mortality rate among patients with the novel coronavirus disease (COVID-19), reports a new study.
Pearl Toh, 3 days ago
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.